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ABSTRACT
The escalating costs of conventional diagnostic technology in oncology have yet to obviate 
futile surgery intervention and the spiralling treatment cost. The evolution in engineering 
technology which looks at the correlation of the anatomy and the function of tumours i.e. 
Positron Emission Tomography-Computed Tomography (PET-CT) have impacted on the 
improved diagnostic accuracy and treatment in oncology. Clinical data have demonstrated that 
the information provided by PET/CT often changes patient management. This review addresses 
the value of PET-CT as a surrogate molecular marker in tumours and to discuss some issues in 
adopting PET/CT in routine daily practice as supported by the numbers of literature reviews 
of its application in oncology since it was first commercialized in 2001. The description of the 
technology used in multimodality imaging has gained encouraging interest among physicians, 
policy makers and insurance companies on the importance of the PET-CT, for which roles are 
not limited to the staging, disease prognostication and treatment monitoring with potential 
impact on treatment cost and justification of radiation safety for the patient. PET/CT  is a useful 
tool in cancer investigation as evidenced by its role as a surrogate marker in underpinning the 
cellular reprogramming of different pathological entities. 
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INTRODUCTION
Most radiologic procedures i.e. Computed 
Tomography (CT) or Magnetic Resonance 
Imaging (MRI) map the morphology 
of tumours with little or no information 
about their metabolism. Positron Emission 
Tomography (PET) employing 2-(fluorine-18) 
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fluoro-2-deoxy-D-glucose (FDG) is being gradually received as an important tool in providing 
qualitative and quantitative metabolic informations that is critical in influencing diagnosis and 
follow-up (Lau et al., 2006; Czernin, 2007). Radio-labelling of the PET tracer, the Flourine-18 
(18(F)) with FDG (glucose analogue) provides an accurate localisation of a cancerous biological 
target via signalling the intracellular glycolysis obtained by the co-registration of the PET and 
CT images (Antti, 2010). The value of combining the FDG-PET and the CT has improved the 
diagnostic accuracy in cancer at large (Fathinul, 2013a; Fathinul et al., 2013b; Nordin, 2012; 
Pfannenberg, 2007; Niikura et al., 2011). For the purpose of this review, we address the utility of 
FDG-PET CT as a useful imaging tool by highlighting its use in the field of oncology imaging. 
Scanning Procedure
PET/CT equipped with a crystal detector arranged in a ring around the patient covering an 
extended 50cm to 70cm per field of view is the common prototype system in commercial use. 
Prior to undergoing a PET/CT examination, patients are required to fast for at least 6 hours 
and to avoid strenuous physical activities. After validating the desired venous glucose level (< 
7.0mmol/L), patients are injected with approximately 10mCi 18F-FDG and are instructed to lie 
completely still in the first 60 minutes in a designated injection room. A CT scan is performed 
for the purpose of an attenuation correction to rescale the 511kV PET data. The PET emission 
acquisition is performed at approximately 3.0 minutes per bed position. PET, CT and fusion 
PET/CT images are displayed on a dedicated PET-CT display system for qualitative and semi-
quantitative analysis (Ronald et al., 2010).
Flurodeoxyglucose (Fdg) as a Signaling Probe for PET/CT
One of the primary metabolic changes associated with proliferating tumour cells is induction 
of aerobic glycolysis. Glucose is a critical nutrient for proliferating cells (Lee et al., 2009). 
Malignant cells have increased facilitated glucose transport and up regulation of hexokinase 
activity; hence, tumours can be identified by regions of increased glucose utilisation (Gatenby 
& Gillies, 2004). FDG is used to signal altered glucose metabolism in patients with malignancy. 
The focal area of abnormally increased FDG uptake is considered suspicious for malignant 
disease, particularly as metabolic changes which often precede the morphological changes are 
associated with disease (Wahl, 1991). Whole-body PET/CT has become the standard of care 
for cancer staging because of its high diagnostic accuracy and ability to provide a rapid survey 
for both regional and distant forms of metastatic disease (Czernin, 2007). 
Qualitative and Semi-quantification of FDG Uptake
The uptake of 18F-FDG can be assessed by qualitative and semi-quantitative means; each has 
its advantages and limitations. Mannus et al. recommended a scheme on the visual interpretation 
of tumour response on PET (Fig.1, Table 1) (MacManus, 2003). Quantitative evaluation of 
FDG PET images provides quantitative data in the form of a standardised uptake value (SUV). 
This is an uptake measurement that provides a mean of comparison of FDG uptake between 
different lesions. Measurement of SUV requires attenuation correction to avoid the variability 
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in FDG uptake due to the differences in tumour habitus within the body. This value normalises 
the tumor FDG uptake with the FDG injected activity and the body weight (Kim, 1994) 
TABLE 1:  Scheme Defining the Different Qualitative Assessment of the Disease Response as Evaluated 
on PET-CT (Macmanus, 2003)
Type of response Description
Complete metabolic response (CMR) -return of 18F-FDG uptake in previously 
documented lesions to a level of equivalent to or 
lower than the activity in normal tissue
Partial metabolic response (PMR) (Fig. 1) -a significant visual reduction in 18F-FDG PET 
uptake in tumour sites on the visual analysis of 
a tumour in question but residual abnormalities 
suggesting malignancy
Progressive metabolic  disease (PMD) -an increase in the extent of metabolic abnormality 
favouring tumour growth or evidence of new sites 
of disease
Stable metabolic disease (SMD) - no change
PET-CT and the Recist Criteria
The standalone structural imaging modality assessment of a small cancer lesion is devoid of 
information on the functional changes. The actual metabolic activity of a cancer is thence 
deemed as under evaluated in important parameters that influence successful treatment as 
cancer healing is confounded by area or fibrosis which mimic the viable cancer tissue. The use 
Fig.1: PET/CT treatment monitoring of a 60-year-old patient with left basal non-small lung carcinoma 
(NSCLC). The left panel: A coronal baseline PET image showing a 3.0 mm left FDG-avid lesion (SUV 
max: 7.56). The right panel: A coronal post-treatment PET image showing partial metabolic response 
of the left NSCLC lesion  (SUV max: 3.17) 
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of Response Evaluation Criteria in Solid Tumours (RECIST 1.1) to criteria in the assessment 
of a lesion does not represent the actual intracellular changes which lead many limitations in 
preparing a patient for an appropriate treatment strategy (Eisenhauera et al., 2009). An instance 
of this is a lymph node of size larger than 1 cm denoted as containing a tumour on the structural 
imaging, which always misleads the treating physician on the nodal staging on the TNM 
AJCC 6th edition (Yan-Ping et al., 2009). The most favourable index of the 18F-FDG PET/
CT is that it is capable of exhibiting more rapid change in cellular metabolism than in tumour 
size (Stroobants et al., 2003). Functional information derived from PET is complementary to 
the high resolution structural imaging data available from such modalities as CT and MRI. 
Because of the limitations of CT scanning, PET/CT scanning may also have a role in response 
assessment after induction therapy prior to surgery, particularly for stage IIIA NSCLC. Choi 
et al. found that the residual metabolic rate of glucose (MRglc) as measured using FDG-PET 
was strongly correlated with response to preoperative chemoradiotherapy in locally advanced 
NSCLC as assessed by a pathological examination of a tumour obtained from a thoracotomy 
(Choi et al., 2002). Currently, the American College of Radiology Imaging Network 6668/
RTOG 0235 trial is prospectively evaluating whether the primary tumour 18F-FDG SUVmax 
shortly after definitive chemoradiation can predict long-term survival in inoperable stage II 
or III NSCLC (Greene et al., 2002). In GIST, Choi et al. confirmed their previous observation 
that RECIST significantly underestimated tumour response. They suggested that a more 
than 10% decrease in one dimension of a cancer lesion on CT at 2 months after treatment is 
adequate to identify good responders to FDG-PET, and predicts a longer long-term prognosis 
(Haesun et al., 2007). The use of contrast-enhanced CT has enabled demonstration of tumour 
characteristics i.e. tumour density, enhancing tumour nodules and tumour vessels, in addition 
to tumour size. The additional information on the tumour enhancement on CT connotes that 
the outside dimensions of a tumour mass may not accurately reflect how active the tumour 
is and the decrease in tumour density of the responding tumours on CT is correlated with the 
development of tumour necrosis or cystic myxoid degeneration.
An evolving new guideline looking at the metabolic changes as a yardstick for post 
treatment evaluation of a solid tumour has been suggested i.e. PET assessment evaluation of a 
solid tumour (PERSIST). However, a lot more work on the factors that confound the parameters 
used before these new criteria are to be accepted given assessment on the metabolic changes 
require more parameters that need standardization (Richard et al., 2009). PERSIST, however, 
offers the potential to characterise the nature of tumour cells on the understanding of the 
alteration of their normal biochemical and biologic features. Thus, the information obtained 
is basically different from that alluded by anatomic imaging. 
FDG PET/CT in Tumor Staging 
Poor sensitivity of standalone CT, MRI and PET may lead to inaccurate staging of a tumour. 
Recent data, with regards to tumour staging, have shown that integrated PET/CT images are 
superior to PET images alone and PET and CT images viewed side by side (Kim, 1994). 
Contrasted CT technique used for the evaluation of equivocal PET results promises higher 
achievable diagnostic results in many tumours (Nordin, 2012), for instance, the prevalence 
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of brown fat FDG-accumulation in patient neuroendocrine tumour. The contrasted CT has a 
greater sensitivity in distinguishing an occult lesion given the raised lesion-to-background 
noise ratio (Yon, 2006; Pottgen, 2006). The impact of PET in detecting diffuse involvement of 
other organ systems as part of the metastatic spread or delineation of the subcentimetre focus 
of FDG-avidity has averted futile surgery and unnecessary treatment costs (Pottgen, 2006). In 
this regards, we observed the change in the patient management as a result of the up-staging 
of tumour by the PET-CT modality (Fathinul, 2011). In addition, the metabolic information on 
the PET image would facilitate the biopsy localisation of a lesion. This is supported by many 
published data on the improved diagnostic yield of biopsy employing PET/CT as compared to 
the conventional approach (Fathinul, 2011; Caroline, 2008). Subcentimeter metastatic lesions 
are better visualised on the PET/CT as compared to CT given the benefit of signalling glycolytic 
metabolism that has improved lesion detection at large (Fig.2) (Yoon, 2011).
Fig.2: Example of discordant positron emission tomography (PET) and computed tomography (CT) 
results. CT (left) images of a mediastinal lymph node showing a subcentimeter lymph node. The 
corresponding PET image (right) exhibited an FDG-avid lymph node denoting the altered glucose 
metabolism suspicious for pathological lymph node. [Images courtesy of Pusat Pengimejan Diagnostik 
Nuklear]
The value of using PET/CT for patients undergoing restaging after treatment is equally 
apparent. It is now possible for this modality to distinguish between malignancy and post-
therapeutic change (Van et al., 2002). According to Selzner et al., combined PET/CT over 
scored standalone CT and PET in restaging tumours after years of disease-free survival, when 
the distorted anatomy may not be easily distinguished from the site of a tumour recurrence 
(Selzner et al., 2004). PET/CT has proven to be a very sensitive non-invasive staging technique 
and may even determine the exact location of a solitary lymph node particularly in evaluating 
the stage of non-small cell lung cancer (NSCLC), thus concluding the precise classification 
as N1 or N2 lymph node station based on classification by the American Joint Committee of 
Cancer (AJCC) (Asamura, 2000). Unsuspected extra thoracic soft tissue or skeletal metastases 
also may be revealed by PET/CT in cases where other imaging methods fail to demonstrate 
distant metastasis (Schoder, 2007). 
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FDG PET/CT Predicts Tumor Aggressiveness 
In addition, the degree of metabolic defect via semi-quantitative analysis, SUV could 
predict tumour aggressiveness and overall patient survival as high SUV values correlate 
with poor disease prognosis (Yamada et al., 1992). We reported 23 patients with recurrent 
phaechromocytoma/paraganglioma, with regards to SUVmax evaluation on tumour 
aggressiveness; nine patients had local controls (34.1%) with mean progression-free survival 
(PFS) of 19.35±3.34 months with a significant number  of patients with metastatic disease who 
had SUV > 9.2 as compared to the local disease group (p<0.05) (Fathinul et al., 2014). The 
prediction of tumour aggressiveness is important for tailoring a management plan obviating 
the risk of unnecessary treatment toxicity and to reduce the cost burden for patients. This is 
in line with many studies which demonstrated that the decrease of FDG uptake after a single 
infusion of chemotherapy was a predictor of eventual response to this regimen (Kostakoglu et 
al., 2002). On the other hand, no decrease of tumour FDG uptake after the first infusion was 
a predictor of non-response.
FDG PET/CT Alters the Management Plan
PET/CT changed the primary diagnosis in approximately 16% of cases, whereas PET/CT 
resulted in a change in staging and treatment plan in approximately 28% to 32% of the 
cases, respectively, and thus enabled the establishment of an appropriate scheme for disease 
response to treatment (Pottgen, 2006). Current procedures to monitor therapy using anatomical 
imaging modalities, such as CT, have a major setback given that functional changes often 
precede anatomical changes. A significant metabolic change can be established by comparing 
the standardised uptake values (SUV) from pre- and post-treatment scans, although such 
comparisons can only be made accurately on attenuation-corrected, quantitative PET images 
(Wahl, 1991). In our experience, we found that in a cohort of 23 patients with head and neck 
tumours, there were changes in the management plan in 58% of the patients being evaluated 
on the PET/CT as compared to CT-based staging (Fathinul, 2013a). 
PET-CT in Radiation Oncology
The new approach of radiation therapy and intensity modulated radiation therapy necessitates 
more precise target volume definitions for dose-sparing of normal tissues. Traditionally, CT 
has been popular as a tool of choice for radiation therapy planning. Nevertheless, CT has been 
shown to have relatively low sensitivity and specificity for detecting tumour tissue (Gregoire, 
2007). In a meta analysis for solid tumours, PET/CT imaging was found to have a better 
sensitivity of 92% and a specificity of 93% compared to 85% and 88% for PET and 64% 
and 83% for CT alone, respectively, and hence for the radiation treatment (Antoch, 2004). 
Tumour biology has been identified as an essential factor for effective dose delivery (Ling 
et al., 2000). With PET/ CT imaging the biological tumour volume allows the radiation dose 
to be modulated according to the distribution of the PET signal intensity within the tumour 
volume specifically (Ling et al., 2000; Schwartz et al., 2005). In addition, the PET-CT provides 
a single reproducible session for highly precise patient positioning during the imaging and 
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treatment sessions rendering an accurate tumour delineation and effective dose delivery over 
standalone PET and CT systems (Gilman, 2007). The proliferating tissue has increased FDG 
avidity although the radiation inflammatory effect may at times be misinterpreted as a true 
positive lesion (Figure 3). A recent review of PET/CT utilisation for radiotherapy planning in 
lung cancer showed differences in the range of 30% to 60% between PET-derived contours 
versus CT-only target volumes (Greco, 2007). 
Fig.3: CT and PET coronal images; A 54-year-old man had completed radiotheraphy of the right lung 
for recurrent NSCLC. The images show typical dome-shape consolidative changes with increased FDG 
accumulation in radiation pneumonitis. (Images courtesy of Peter Mac Callum Centre)
PET/CT and the Radiation Risk
Most commonly, PET utilises 18F-FDG as a radiotracer; the short half-life of 110 min reduces 
radiation exposure compared with other commonly used radionuclides such as 99mTechnetium 
(6 hours) or  201Thallium (72 hours). It carries a low absorbed dose to the patient estimated at 
approximately 7 mSv. The radiation (X-rays) from our diagnostic CT protocol ranged from 
8mSv to 16 mSv for a two-dedicated low tube current dose (35mAs) and the CARE Dose 4D 
(120kV). The 64-multislice CT technique was equipped with the dual focal spot that ensured 
more image yields without increase in the total radiation dose and the CARE dose 4D is capable 
of modulating tube current adaptation tailoring to the patient’s size, for which features render 
an efficient effective patient dose of up to 20% as compared to the lower 16 multislice of the 
same kind (Zito, 2009). In general, the benefits of subjecting patients for the PET-CT outweigh 
the radiation risk as most information required for the staging of a tumour is available in a 
single session study. In a study by Hishar et al., the dose minimisation strategy on PET was 
adequate to yield a good PET-CT image without significant compromise (Hishar, 2014).
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PET-CT and Economy
Despite increasing evidence supporting the accuracy of standalone imaging i.e. CT, MRI or 
PET, high cost and limited cost-effectiveness data have militated against funding for routine 
clinical use in many countries (Gambhir, 1996). There is now substantial evidence that PET/CT 
is an exceedingly accurate multimodality imaging in detecting malignant tissue and provides 
a higher specificity than conventional imaging (Michael et al., 2011; Ell, 2006). Precision in 
staging may avert futile surgery for which PET-CT has changed the management plan whilst 
providing additional clinical benefits to patients (Ell, 2006). Considering the median length 
of pre- and post-operative hospital stay, the cost of surgical resections and biopsies evaluated 
on PET-CT was found overall to be cost beneficial (Rohren, 2004). In Heinrich et al.’s trial on 
patients with pancreatic cancers who underwent PET-CT for disease staging, metastases were 
found in 16 patients with cancer initially deemed resectable, leading to different management 
and cost savings of USD 1,066 per patient (Heinrich et al., 2005). In the United States, the 
use of FDG PET scanning has been shown to be a cost-effective alternative to conventional 
imaging methods in the evaluation of non-small-cell lung cancer, and this led MEDICARE, 
an insurance provider, to reimburse patients for those indications (Dewan, 1995). In our initial 
experience in working with patients with cancers referred for staging, a remarkable change 
in management strategy reflected a potential reduction in the total costs incurred to be borne 
by the patients.  
PET-CT Potential Pitfalls 
As PET and CT are operated on a sequential basis, where co-registration of data obtained from 
both methods is deemed to some degradation artefacts. The use of contrasted CT in PET/CT; 
among other known artefacts the following were seen: banana lesion caused by  diaphragmatic 
movement in the lower lung; breathing artefacts; patient motion; incidental metal device on 
the patient torso or FDG-RBC microembolus; leakage of FDG at the injection site or from 
the contaminated patient’s gown after urine voiding; and pooling of intravenous contrast as 
source of false positive FDG-avidity were also observed as an attribute to the overestimation 
of the attenuation correction (Fathinul & Lau, 2009a; Fathinul & Lau, 2009b; William, 2007). 
Therefore, a careful instruction for PET/CT preparation and adoption of improved techniques 
during PET-CT i.e. gated respiration and improvement of the PET detector to facilitate image 
enhancement are urgently required. 
CONCLUSION
A combined PET and CT scanner is a practical and effective approach in acquiring co-
registered anatomical and functional images in a single scanning session. It denotes the new 
era in molecular imaging whereby advancement in science and technology has impacted the 
way physicians personalise treatment plans with more effective strategy and a cost effective 
package for the patient. Combined contrasted PET/CT imaging facilitates the separation of 
normal physiologic uptake from pathological tissue with a more favourable accuracy and, 
hence, helps reduce the incidence of false-positive and false-negative incidence.
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